Effectiveness of ustekinumab in postoperative Crohn's disease management: Evidence from a Chinese multicenter cohort

Table 3 Multivariate generalized estimation equations analysis of factors associated with a Rutgeerts score improvement (n = 71)

Variable	β	Robust SE	Wald χ²	OR (95%CI)	P value
Intercept	-3.709	1.351	7.532	0.025 (0.002-0.346)	0.006
Treatment line
First-line UST therapy (vs second-line)	0.546	0.258	4.498	1.727 (1.042-2.862)	0.034
Montreal classification
Age A2 (17-40 years) vs A1 (≤ 16 years)	2.411	1.122	4.621	11.149 (1.237-100.482)	0.032
Age A3 (> 40 years) vs A1 (≤ 16 years)	1.083	0.301	12.927	2.953 (1.637-5.329)	< 0.001
Location L2 (colonic) vs L1 (ileal)	1.171	1.014	1.334	3.225 (0.442-23.527)	0.248
Location L3 (ileocolonic) vs L1 (ileal)	1.342	1.022	1.725	3.827 (0.517-28.348)	0.189
Behavior B2 (stricturing) vs B1 (non-stricturing, non-penetrating)	1.325	0.661	4.023	3.764 (1.031-13.742)	0.045
Behavior B3 (penetrating) vs B1 (non-stricturing, non-penetrating)	2.459	1.203	4.179	11.692 (1.107-123.521)	0.041
Perianal disease (yes vs no)	-1.208	1.165	1.074	0.299 (0.030-2.934)	0.300
Other clinical factors
Extraintestinal manifestations (yes vs no)	0.613	0.459	1.783	1.847 (0.750-4.544)	0.182
Disease duration (years)	-0.021	0.007	10.431	0.979 (0.967-0.992)	0.001
Pre-UST Rutgeerts score	0.607	0.331	3.369	1.835 (0.960-3.509)	0.066

Model information: (1) Dependent variable: Rutgeerts score improvement (0 = no, 1 = yes); (2) Analysis method: Generalized estimating equations; and (3) Reference categories: Second-line, Age A1, location L1, behavior B1, no perianal disease and no extraintestinal manifestations. UST: Ustekinumab.